Article Text

PDF
Angiogenesis blockade as a new therapeutic approach to experimental colitis
  1. Silvio Danese1,
  2. Miquel Sans2,
  3. David M Spencer3,
  4. Ivy Beck4,
  5. Fernando Doñate4,
  6. Marian L Plunkett4,
  7. Carol de la Motte5,
  8. Raymond Redline6,
  9. David E Shaw7,
  10. Alan D Levine3,
  11. Andrew P Mazar4,
  12. Claudio Fiocchi5
  1. 1Division of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
  2. 2Department of Gastroenterology, Hospital Clinic i Provincial/ IDIBAPS, CIBER-EHD, Barcelona, Spain
  3. 3Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
  4. 4Attenuon, LLC, San Diego, California, USA
  5. 5Department of Pathobiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
  6. 6Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA
  7. 7DE Shaw Research and Development, New York, New York, USA
  1. Correspondence to:
    Dr S Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milan 20089, Italy; sdanese{at}hotmail.com

Abstract

Background: Neoangiogenesis is a critical component of chronic inflammatory disorders. Inhibition of angiogenesis is an effective treatment in animal models of inflammation, but has not been tested in experimental colitis.

Aim: To investigate the effect of ATN-161, an anti-angiogenic compound, on the course of experimental murine colitis.

Method: Interleukin 10-deficient (IL10−/−) mice and wild-type mice were kept in ultra-barrier facilities (UBF) or conventional housing, and used for experimental conditions. Dextran sodium sulphate (DSS)-treated mice were used as a model of acute colitis. Mice were treated with ATN-161 or its scrambled peptide ATN-163. Mucosal neoangiogenesis and mean vascular density (MVD) were assessed by CD31 staining. A Disease Activity Index (DAI) was determined, and the severity of colitis was determined by a histological score. Colonic cytokine production was measured by ELISA, and lamina propria mononuclear cell proliferation by thymidine incorporation.

Result: MVD increased in parallel with disease progression in IL10−/− mice kept in conventional housing, but not in IL10−/− mice kept in UBF. Angiogenesis also occurred in DSS-treated animals. IL10−/− mice with established disease treated with ATN-161, but not with ATN-163, showed a significant and progressive decrease in DAI. The histological colitis score was significantly lower in ATN-161-treated mice than in scrambled peptide-treated mice. Inhibition of angiogenesis was confirmed by a significant decrease of MVD in ATN-161-treated mice than in ATN-163-treated mice. No therapeutic effects were observed in the DSS model of colitis. ATN-161 showed no direct immunomodulatory activity in vitro.

Conclusion: Active angiogenesis occurs in the gut of IL10−/− and DSS-treated colitic mice and parallels disease progression. ATN-161 effectively decreases angiogenesis as well as clinical severity and histological inflammation in IL10−/− mice but not in the DDS model of inflammatory bowel disease (IBD). The results provide the rational basis for considering anti-angiogenic strategies in the treatment of IBD in humans.

  • DAI, Disease Activity Index
  • DSS, dextran sodium sulphate
  • IBD, inflammatory bowel disease
  • IL, interleukin
  • IP, intraperitoneal
  • LPMC, lamina propria mononuclear cells
  • LPS, lipopolysaccharide
  • MVD, mean vascular density
  • PBS, phosphate-buffered saline
  • UBF, ultra-barrier facility
  • VEGF, vascular endothelial growth factor
  • WT, wild type

Statistics from Altmetric.com

Footnotes

  • Published Online First 14 December 2006

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.